Darolutamide is a medicine used to treat prostate cancer. It works by blocking male hormones like testosterone from helping the cancer grow. It's taken as a pill by mouth.
Every report comes from a Lived member, sent anonymously.
Have you tried Nubeqa (Darolutamide) for Prostate Cancer?
Darolutamide, sold under the brand name Nubeqa, is a prescription pill for adults with prostate cancer, a cancer whose growth is usually fueled by male hormones such as testosterone. It is approved for two situations, and in both it is added to ongoing testosterone-lowering treatment rather than replacing it. The first is non-metastatic castration-resistant prostate cancer. Castration-resistant means the cancer keeps growing, often shown by a rising PSA (prostate-specific antigen) blood test, even though testosterone has been lowered. Non-metastatic means scans have not found the cancer in distant parts of the body. Here the goal is to delay spread. The second is metastatic castration-sensitive prostate cancer: cancer that has spread beyond the prostate but still responds to lowering testosterone. In this setting darolutamide can be used on its own or together with docetaxel, a chemotherapy medicine given by injection.
Male hormones, called androgens, drive prostate cancer by attaching to a protein inside the cancer cell called the androgen receptor. Once a hormone is attached, the receptor moves into the cell's nucleus and switches on genes that help the cell grow and divide. Darolutamide is an androgen receptor inhibitor. It blocks this chain at several points: it stops the hormone from attaching, stops the receptor from entering the nucleus and stops it from switching on those genes. Testosterone-lowering treatment reduces the supply of hormone, and darolutamide blocks the signal from whatever hormone remains, which is why the two are used together.
Nubeqa comes as 300 mg tablets. The usual dose is two tablets twice a day, taken with food and swallowed whole. People with severe kidney disease who are not on dialysis, or with moderate liver disease, are usually prescribed a lower dose. The prescriber may also lower the dose or pause treatment if side effects become hard to manage. Darolutamide works alongside a testosterone-lowering medicine known as GnRH (gonadotropin-releasing hormone) therapy, which should continue throughout treatment unless both testicles have been surgically removed. When darolutamide is combined with docetaxel, the first of six chemotherapy cycles is usually given within six weeks of starting the tablets, and the tablets can continue even if a chemotherapy cycle is delayed or stopped. If a dose is missed, take it as soon as you remember, up to the time of the next scheduled dose. The Nubeqa label allows that one missed dose to be taken together with the next scheduled dose if needed, after which the regular twice-daily schedule resumes. If you are unsure what to do, check with the pharmacist or care team.
Taken without chemotherapy, darolutamide's most noticeable side effect is tiredness: in the main trial, about 16 in 100 people taking it reported fatigue, compared with 11 in 100 taking a placebo. Pain in the arms or legs and rash were less common. Many other changes show up only on blood tests, such as raised liver enzymes, a higher level of bilirubin (a substance the liver processes) and a lower count of neutrophils, the white blood cells that fight infection. Taken with docetaxel, constipation, rash, reduced appetite, bleeding (for example blood in the urine or nosebleeds), weight gain and higher blood pressure were more common than with docetaxel alone. Anemia, high blood sugar and low calcium were also common on blood tests, but about as common with docetaxel alone, so they mostly reflect the chemotherapy regimen. Two less common risks matter. Darolutamide has been linked to ischemic heart disease, meaning reduced blood flow to the heart, including some deaths. Chest pain or discomfort, at rest or with activity, or shortness of breath needs medical help right away. Seizures are uncommon, but a seizure or any loss of consciousness should be reported to the care team right away.
Some medicines change how much darolutamide stays in the body. Rifampin, an antibiotic mainly used for tuberculosis, and similar drugs that speed up darolutamide's breakdown, such as the older seizure medicines carbamazepine and phenytoin and the herbal supplement St. John's wort, can lower its levels enough to make it less effective, so they should be avoided. Darolutamide can also raise the levels of certain other drugs. For example, it increased levels of rosuvastatin, a cholesterol-lowering statin, about fivefold, which can make that drug's side effects more likely, so the prescriber may avoid the combination or lower the statin dose. Tell the prescriber and pharmacist about every medicine, vitamin and herbal supplement, and check before starting or stopping one. To lower the heart risk described under Side Effects, keeping high blood pressure, diabetes and high cholesterol well managed is part of treatment. Mention any history of seizures, brain injury, stroke or brain tumor before starting, and think about the seizure risk before activities where suddenly passing out could put you or others in danger. Darolutamide can harm a developing baby and cause miscarriage. Men whose partners could become pregnant should use effective contraception during treatment and for one week after the last dose. It may also reduce fertility, which is worth raising before treatment if fathering children matters. It has not been shown to be safe or effective in women or children.
Darolutamide works in the background. Its purpose is to hold the cancer back rather than to relieve symptoms quickly. In the main trial for non-metastatic castration-resistant cancer, the typical time before the cancer spread or the person died was about 40 months with darolutamide, compared with about 18 months with placebo. People taking it also lived longer overall, and it delayed worsening pain and the need for chemotherapy. For metastatic cancer, adding darolutamide to docetaxel improved survival: during the study, about 35 in 100 people taking darolutamide died, compared with 46 in 100 taking a placebo. Used without chemotherapy for metastatic cancer, it delayed growth seen on scans, but a survival benefit was not proven. Treatment usually continues for as long as the cancer stays under control and side effects remain manageable. Follow-up visits typically include blood tests, attention to blood pressure and heart health, and scans to see whether the cancer is growing. If it does progress, the care team will discuss the next treatment options.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Nubeqa (Darolutamide), what you've noticed, or ask the community a question.